Clinical Trials

JBCRG-C14(DAHLIA)
NEW

A Multicenter Retrospective Cohort Study Evaluating the Efficacy and Safety of Datopotamab Deruxtecan for Patients with Hormone Receptor-positive HER2 Negative Inoperable or Recurrent Breast Cancer in Japan

Status
Now Recruiting

Objectives
The objective is to evaluate the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in patients with inoperable or recurrent breast cancer in a real-world clinical setting.

Subjects
Hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancer

Endpoints
Primary endpoint
1) Real world progression free survival (rwPFS)

Secondary endpoints
1) Time to next treatment (TTNT)
2) Time to treatment failure (TTF)
3) TTF2
4) rwPFS2
5) Overall survival(OS)
6) Adverse event rate
7) Interstitial lung disease(ILD), Oral mucositis, Time to first occurrence of ocular surface events
8) Relative dose intensity of Dato-DXd
9) Percentage of patients receiving subsequent treatment regimens after Dato-DXd treatment

Trial Period
From Research Approval Date to 31. Dec. 2028

Lead Principal Investigator
Yoichi Naito (General Internal Medicine, National Cancer Center Hospital East)

Target Sample Size
300

Regimen
This is a multicenter, retrospective cohort study designed to collect data on treatment administration, disease progression, and the occurrence of adverse events for all breast cancer patients who began receiving Dato-DXd for the first time between March 19, 2025, and December 31, 2025.

Source of Funding
DAIICHI SANKYO COMPANY, LIMITED

Conference Presentation

Articles and Publications

UMIN-ID

jRCT
jRCT1031250721

Memo

COI Disclosure

Previous PageClinical Trials